Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.79 -3.0%	$9.54	$7.35 ▼ $13.70	$2.73B	0.11	330,311 shs	285,194 shs
CPRX Catalyst Pharmaceuticals	$21.12 -1.0%	$22.63	$15.34 ▼ $26.58	$2.60B	0.7	1.21 million shs	999,536 shs
DNTH Dianthus Therapeutics	$20.59 -0.4%	$19.06	$13.36 ▼ $32.27	$664.75M	1.43	352,897 shs	370,878 shs
MIRM Mirum Pharmaceuticals	$52.02 +0.7%	$49.71	$36.20 ▼ $54.78	$2.56B	0.94	351,958 shs	337,696 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-2.98%	-8.53%	-1.57%	+6.93%	-24.87%
CPRX Catalyst Pharmaceuticals	-0.98%	+0.72%	-1.54%	-14.98%	+22.51%
DNTH Dianthus Therapeutics	-0.39%	-4.23%	+12.02%	-5.12%	-30.86%
MIRM Mirum Pharmaceuticals	+0.66%	+0.37%	+5.97%	+19.07%	+28.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	3.3792 of 5 stars	3.5	4.0	0.0	3.4	0.0	1.9
CPRX Catalyst Pharmaceuticals	4.8982 of 5 stars	3.6	1.0	3.9	4.0	3.3	3.8
DNTH Dianthus Therapeutics	1.2237 of 5 stars	3.5	2.0	0.0	0.0	0.8	0.0
MIRM Mirum Pharmaceuticals	3.7376 of 5 stars	3.6	0.0	4.2	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$14.00	59.27% Upside
CPRX Catalyst Pharmaceuticals	3.25	Buy	$32.83	55.46% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$53.00	157.41% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	25.91% Upside

Current Analyst Ratings Breakdown

Latest DNTH, ALVO, MIRM, and CPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/5/2025	CPRX Catalyst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	DNTH Dianthus Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $50.00
5/13/2025	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.39	N/A	N/A	($1.37) per share	-6.42
CPRX Catalyst Pharmaceuticals	$491.73M	5.24	$2.42 per share	8.72	$6.10 per share	3.46
DNTH Dianthus Therapeutics	$6.24M	106.12	N/A	N/A	$11.91 per share	1.73
MIRM Mirum Pharmaceuticals	$336.89M	7.65	N/A	N/A	$4.70 per share	11.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	23.76	43.95	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
CPRX Catalyst Pharmaceuticals	$163.89M	$1.57	13.45	9.92	0.87	36.91%	42.45%	36.59%	8/6/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$2.88	N/A	N/A	N/A	-1,544.23%	-29.26%	-27.87%	8/6/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)

Latest DNTH, ALVO, MIRM, and CPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	ALVO Alvotech	-$0.06	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	CPRX Catalyst Pharmaceuticals	$0.57	N/A	N/A	N/A	$140.42 million	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q1 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.82	+$0.04	-$0.82	$0.81 million	$1.16 million
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CPRX Catalyst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
CPRX Catalyst Pharmaceuticals	N/A	6.14	5.96
DNTH Dianthus Therapeutics	N/A	15.98	15.99
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CPRX Catalyst Pharmaceuticals	79.22%
DNTH Dianthus Therapeutics	47.53%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
CPRX Catalyst Pharmaceuticals	10.40%
DNTH Dianthus Therapeutics	8.15%
MIRM Mirum Pharmaceuticals	14.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
CPRX Catalyst Pharmaceuticals	80	121.97 million	109.29 million	Optionable
DNTH Dianthus Therapeutics	80	32.16 million	29.54 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	42.42 million	Optionable

DNTH, ALVO, MIRM, and CPRX Headlines

Recent News About These Companies

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $65.50 Consensus Price Target from Brokerages

August 2 at 2:17 AM | americanbankingnews.com

Mirum Pharmaceuticals (MIRM) Projected to Post Quarterly Earnings on Wednesday

July 31 at 7:58 AM | marketbeat.com

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

July 30 at 11:07 AM | zacks.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by GSA Capital Partners LLP

July 29, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Buy" from Analysts

July 28, 2025 | marketbeat.com

Knights of Columbus Asset Advisors LLC Has $890,000 Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

July 27, 2025 | marketbeat.com

Bank of New York Mellon Corp Acquires 122,402 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

July 21, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Holdings Lowered by Atle Fund Management AB

July 19, 2025 | marketbeat.com

New York State Common Retirement Fund Acquires 32,015 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

July 18, 2025 | marketbeat.com

Mirum Gains 35% in 3 Months: How Should You Play the Stock?

July 17, 2025 | zacks.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Sets New 12-Month High - Here's Why

July 14, 2025 | marketbeat.com

Mirum Pharmaceuticals price target raised to $76 from $68 at Evercore ISI

July 12, 2025 | msn.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025 | businesswire.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Lowered to Hold Rating by Wall Street Zen

July 6, 2025 | marketbeat.com

Jolanda Howe Sells 477 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

July 4, 2025 | insidertrades.com

Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 477 Shares of Stock

July 3, 2025 | marketbeat.com

Jolanda Howe Sells 564 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

July 3, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages

July 3, 2025 | marketbeat.com

Liver Drug Stock Rockets 236% Amid FDA Approval As Sales Accelerate; Funds Load Up

June 17, 2025 | msn.com

Mirum Pharmaceuticals Inc.

June 11, 2025 | barrons.com

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNTH, ALVO, MIRM, and CPRX Company Descriptions

Alvotech NASDAQ:ALVO

$8.79 -0.27 (-2.98%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$8.79 0.00 (0.00%)

As of 08/1/2025 06:31 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Catalyst Pharmaceuticals NASDAQ:CPRX

$21.12 -0.21 (-0.98%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.06 -0.05 (-0.26%)

As of 08/1/2025 07:59 PM Eastern

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.

Dianthus Therapeutics NASDAQ:DNTH

$20.59 -0.08 (-0.39%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$21.00 +0.41 (+1.99%)

As of 08/1/2025 04:18 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Mirum Pharmaceuticals NASDAQ:MIRM

$52.02 +0.34 (+0.66%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$52.01 -0.01 (-0.02%)

As of 08/1/2025 05:21 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time